This study is looking at candidemia, which is a serious infection caused by a type of yeast called Candida that enters the bloodstream. The study will test different durations of treatment using antifungal medications, which are drugs that fight fungal infections. The medications that may be used in this study include anidulafungin, caspofungin, micafungin, amphotericin B liposome, fluconazole, and voriconazole. These medications work to eliminate the yeast infection from the blood.
The purpose of the study is to find out if treating uncomplicated candidemia, which means the infection has not spread to other parts of the body, for 7 days after the first blood test shows no more yeast is as effective as treating it for 14 days after that first clear blood test. The study will compare how many patients are alive 28 days after their first negative blood culture between the two treatment durations. Patients in the study will receive one of the antifungal medications mentioned above, and the length of treatment will depend on which group they are randomly assigned to.
During the study, patients will have blood tests to check their liver function and to confirm that the infection has cleared. The study will also track whether the infection comes back or spreads to other parts of the body. Patients will be followed for up to 45 days to monitor their recovery and check for any signs that the infection has returned. The study will also look at the costs associated with each treatment duration to understand the economic impact of the different approaches.
France 
